Treeline Bioscience Inc.

Venture capital fundraising by biopharmaceutical companies rose to $7.11bn in the fourth quarter of 2024, after falling to $6.46bn in Q3 from $7.95bn in Q2, according to data from Evaluate. But the ye

PureTech Health plc, after the multibillion-dollar success of its last neuropsychiatry venture Karuna Therapeutics Inc., launched Seaport Therapeutics in April with $100m in series A funding and on 21

Since biotech valuations on public markets peaked in September 2021, the sector has had to contend with reduced financing availability and harsher conditions for deal-making. In December 2023, Scrip

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Busy Moderna Inks Gene-Editing Pact Wit